Shopping Cart 0
Cart Subtotal
USD 0

Puretech Health plc (PRTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It also develops technology and products for screening, diagnosis, and treatment of neurological disorders such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. The company offers key experiments and de-risking programs for developing and launching new therapeutics. It markets its products across the US. Puretech is headquartered in Boston, Massachusetts, the US.

Puretech Health plc (PRTC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10

Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Puretech Health plc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Karuna Pharma Raises USD42 Million in Series A Financing 13

resTORbio Raises USD40 Million in Series B Financing 15

resTORbio Raises USD25 Million in Series A Financing 16

Vedanta Biosciences Raises USD50 Million in Venture Financing 17

Gelesis Raises USD31.5 Million in Financing Round 18

Gelesis Raises USD12 Million in Venture Financing 19

Vedanta Biosciences Raises Funds Through Venture Financing 20

DiaTech Oncology Raises USD 1.2 Million In Seed Financing 21

Partnerships 22

Akili Interactive Enters into Licensing Agreement with University of California 22

PureTech Health Enters into Co-Development Agreement with Roche 23

Entrega Enters into Agreement with Eli Lilly and Co 24

Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26

Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27

Vedanta Biosciences Expands Agreement with NYU Langone Medical 28

Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29

Knode Enters Into Co-Development Agreement With AstraZeneca 30

Licensing Agreements 31

Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31

PureTech Health Enters into Licensing Agreement with 3P Biotech 32

Commense Enters into Licensing Agreement with University of British Columbia 33

PureTech Amends Licensing Agreement with Novartis 34

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35

Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36

Equity Offering 37

Puretech Health Raises USD100 Million in Private Placement of Shares 37

resTORbio Raises USD97.8 Million in IPO of Shares 38

PureTech Health Spin Off Nybo Therapeutics 39

PureTech Raises USD195 Million in IPO 40

Debt Offering 41

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Puretech Health plc-Key Competitors 42

Puretech Health plc-Key Employees 43

Puretech Health plc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Financial Announcements 46

Sep 11, 2018: PureTech Health- Half-Year Report 46

Apr 16, 2018: PureTech Health Announces Annual Results for Year Ended 31 December 2017 49

Aug 30, 2017: PureTech Health: Half-Year Report For Month Ended 30 June 2017 54

Apr 06, 2017: PureTech Health Announces Annual Results for Year Ended 31 December 2016 56

Corporate Communications 60

Oct 17, 2018: PureTech's Karuna adds Jeff Jonas, MD, to board of directors 60

Jun 05, 2018: PureTech's Gelesis Appoints Harry Leider, former Walgreens Chief Medical Officer, as Chief Medical Officer and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, to Board of Directors 61

May 02, 2018: PureTech Health Affiliate Sonde Adds Thai Lee to Board of Directors 62

Apr 24, 2018: PureTech Health Appoints Joep Muijrers as Chief Financial Officer 64

Apr 09, 2018: PureTech's Commense Appoints President and Chief Executive Officer 65

Feb 20, 2018: PureTech Health: Trading Statement 66

Jan 03, 2018: PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors 70

Jun 28, 2017: PureTech Health's Akili Appoints Former Cubist CEO, Rob Perez, as Executive Chairman 71

Apr 13, 2017: resTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer 73

Mar 02, 2017: PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy 74

Feb 23, 2017: PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer 75

Product News 76

Sep 17, 2018: Puretech Health collaborator publishes in nature neuroscience highlighting key role of brain lymphatics in neuroinflammatory conditions like multiple sclerosis 76

May 09, 2017: PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections 77

04/11/2017: PureTech Health Advances New Programme Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms 78

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Puretech Health plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10

Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karuna Pharma Raises USD42 Million in Series A Financing 13

resTORbio Raises USD40 Million in Series B Financing 15

resTORbio Raises USD25 Million in Series A Financing 16

Vedanta Biosciences Raises USD50 Million in Venture Financing 17

Gelesis Raises USD31.5 Million in Financing Round 18

Gelesis Raises USD12 Million in Venture Financing 19

Vedanta Biosciences Raises Funds Through Venture Financing 20

DiaTech Oncology Raises USD 1.2 Million In Seed Financing 21

Akili Interactive Enters into Licensing Agreement with University of California 22

PureTech Health Enters into Co-Development Agreement with Roche 23

Entrega Enters into Agreement with Eli Lilly and Co 24

Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26

Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27

Vedanta Biosciences Expands Agreement with NYU Langone Medical 28

Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29

Knode Enters Into Co-Development Agreement With AstraZeneca 30

Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31

PureTech Health Enters into Licensing Agreement with 3P Biotech 32

Commense Enters into Licensing Agreement with University of British Columbia 33

PureTech Amends Licensing Agreement with Novartis 34

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35

Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36

Puretech Health Raises USD100 Million in Private Placement of Shares 37

resTORbio Raises USD97.8 Million in IPO of Shares 38

PureTech Health Spin Off Nybo Therapeutics 39

PureTech Raises USD195 Million in IPO 40

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Puretech Health plc, Key Competitors 42

Puretech Health plc, Key Employees 43

Puretech Health plc, Other Locations 44

Puretech Health plc, Subsidiaries 44

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Puretech Health plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It also develops technology and products for screening, diagnosis, and treatment of neurological disorders such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. The company offers key experiments and de-risking programs for developing and launching new therapeutics. It markets its products across the US. Puretech is headquartered in Boston, Massachusetts, the US.

Puretech Health plc (PRTC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10

Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Puretech Health plc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Karuna Pharma Raises USD42 Million in Series A Financing 13

resTORbio Raises USD40 Million in Series B Financing 15

resTORbio Raises USD25 Million in Series A Financing 16

Vedanta Biosciences Raises USD50 Million in Venture Financing 17

Gelesis Raises USD31.5 Million in Financing Round 18

Gelesis Raises USD12 Million in Venture Financing 19

Vedanta Biosciences Raises Funds Through Venture Financing 20

DiaTech Oncology Raises USD 1.2 Million In Seed Financing 21

Partnerships 22

Akili Interactive Enters into Licensing Agreement with University of California 22

PureTech Health Enters into Co-Development Agreement with Roche 23

Entrega Enters into Agreement with Eli Lilly and Co 24

Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26

Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27

Vedanta Biosciences Expands Agreement with NYU Langone Medical 28

Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29

Knode Enters Into Co-Development Agreement With AstraZeneca 30

Licensing Agreements 31

Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31

PureTech Health Enters into Licensing Agreement with 3P Biotech 32

Commense Enters into Licensing Agreement with University of British Columbia 33

PureTech Amends Licensing Agreement with Novartis 34

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35

Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36

Equity Offering 37

Puretech Health Raises USD100 Million in Private Placement of Shares 37

resTORbio Raises USD97.8 Million in IPO of Shares 38

PureTech Health Spin Off Nybo Therapeutics 39

PureTech Raises USD195 Million in IPO 40

Debt Offering 41

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Puretech Health plc-Key Competitors 42

Puretech Health plc-Key Employees 43

Puretech Health plc-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 46

Financial Announcements 46

Sep 11, 2018: PureTech Health- Half-Year Report 46

Apr 16, 2018: PureTech Health Announces Annual Results for Year Ended 31 December 2017 49

Aug 30, 2017: PureTech Health: Half-Year Report For Month Ended 30 June 2017 54

Apr 06, 2017: PureTech Health Announces Annual Results for Year Ended 31 December 2016 56

Corporate Communications 60

Oct 17, 2018: PureTech's Karuna adds Jeff Jonas, MD, to board of directors 60

Jun 05, 2018: PureTech's Gelesis Appoints Harry Leider, former Walgreens Chief Medical Officer, as Chief Medical Officer and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, to Board of Directors 61

May 02, 2018: PureTech Health Affiliate Sonde Adds Thai Lee to Board of Directors 62

Apr 24, 2018: PureTech Health Appoints Joep Muijrers as Chief Financial Officer 64

Apr 09, 2018: PureTech's Commense Appoints President and Chief Executive Officer 65

Feb 20, 2018: PureTech Health: Trading Statement 66

Jan 03, 2018: PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors 70

Jun 28, 2017: PureTech Health's Akili Appoints Former Cubist CEO, Rob Perez, as Executive Chairman 71

Apr 13, 2017: resTORbio Appoints Joan Mannick, M.D., as Chief Medical Officer 73

Mar 02, 2017: PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as President and Chief of Business and Strategy 74

Feb 23, 2017: PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer 75

Product News 76

Sep 17, 2018: Puretech Health collaborator publishes in nature neuroscience highlighting key role of brain lymphatics in neuroinflammatory conditions like multiple sclerosis 76

May 09, 2017: PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections 77

04/11/2017: PureTech Health Advances New Programme Targeting Immunosuppressive Gamma Delta T Cells and Related Mechanisms 78

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Puretech Health plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Puretech Health plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Puretech Health plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Puretech Health plc, Deals By Therapy Area, 2012 to YTD 2018 9

Puretech Health plc, Medical Devices Deals, 2012 to YTD 2018 10

Puretech Health plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Karuna Pharma Raises USD42 Million in Series A Financing 13

resTORbio Raises USD40 Million in Series B Financing 15

resTORbio Raises USD25 Million in Series A Financing 16

Vedanta Biosciences Raises USD50 Million in Venture Financing 17

Gelesis Raises USD31.5 Million in Financing Round 18

Gelesis Raises USD12 Million in Venture Financing 19

Vedanta Biosciences Raises Funds Through Venture Financing 20

DiaTech Oncology Raises USD 1.2 Million In Seed Financing 21

Akili Interactive Enters into Licensing Agreement with University of California 22

PureTech Health Enters into Co-Development Agreement with Roche 23

Entrega Enters into Agreement with Eli Lilly and Co 24

Vedanta Biosciences Enters into Agreement with Leiden University and Mitchell Cancer 25

Vedanta Biosciences Enters into Agreement with Stanford University School of Medicine 26

Vedanta Biosciences Enters into Agreement with Leiden University Medical Center 27

Vedanta Biosciences Expands Agreement with NYU Langone Medical 28

Vedanta Biosciences Enters into Agreement with NYU Langone Medical Center 29

Knode Enters Into Co-Development Agreement With AstraZeneca 30

Vedanta Biosciences Enters into Licensing Agreement with JSR Corp 31

PureTech Health Enters into Licensing Agreement with 3P Biotech 32

Commense Enters into Licensing Agreement with University of British Columbia 33

PureTech Amends Licensing Agreement with Novartis 34

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 35

Vedanta Biosciences Enters into Licensing Agreement with Riken, University of Tokyo, and Azabu University 36

Puretech Health Raises USD100 Million in Private Placement of Shares 37

resTORbio Raises USD97.8 Million in IPO of Shares 38

PureTech Health Spin Off Nybo Therapeutics 39

PureTech Raises USD195 Million in IPO 40

Karuna Pharma Raises USD3.4 Million in Private Placement of Notes 41

Puretech Health plc, Key Competitors 42

Puretech Health plc, Key Employees 43

Puretech Health plc, Other Locations 44

Puretech Health plc, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Puretech Health plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.